Outcome Of Trans- Arterial Chemo Embolization (TACE) In Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis

Thesis

Submitted for Partial Fulfillment of Master Degree in Tropical Medicine BY

Sayed Ahmed Sayed

M.B.B.CH

Under the supervision of

Ass. Prof. Heba Mohamed Abdella

Assistant professor of Tropical Medicine Faculty of Medicine-Ain Shams University

Dr/Iman Mohamed Fawzy Montasser

Lecturer of Tropical Medicine
Faculty of Medicine -Ain Shams University

Dr/ Mohamed Sobhi Hassan

Lecturer of diagnostic radiology

Faculty of Medicine -Ain Shams University

Faculty of Medicine

Ain Shams University

2015



سورة البقرة الآية: ٣٢



First of all, I would like to thank Allah for His grace and mercy and for giving me the effort to complete this work.

I would like to express my deepest gratitude and great respect to **Dr**, **Heba Mohamed Abdella** assistant Professor of Tropical Medicine, under whose supervision I had the honor and pleasure to proceed with work. Her constant guidance, encouragement and foresight made all the difference.

I'd like to express my deepest thanks to **Dr. Iman**Mohamed Fawzy, lecturer of Tropical Medicine, for her continuous guidance and encouragement.

My deepest appreciation goes to **Dr. Mohamed**Sobhy Hassan, lecturer of Radiodiagnosis, for his valuable suggestions, advice, efforts, creativity and offering me his precious time for technical experience.

And last but, by no means least, I would like to thank members of HCC group for their great help, outstanding support, active participation and continuous guidance, without which this work could not be done.

Finally I'd like to thank all my family members and my future wife for their constant support and guidance all through this work.

نتائج الحقن الكيماوى عبر الشريان الكبدى في مرضى سرطان الخلايا الكبديه المصاحبه بالتخثر الجزئي بالوريد البابي رسالة

توطئة للحصول على درجة الماجستير فى طب المناطق الحارة مقدمة من

الطبيب/ سيد أحمد سيد بكالوريوس الطب والجراحة كلية الطب - جامعة عين شمس إشراف

الدكتور / هبه محمد عبد الا

أستاذ مساعد طب المناطق الحارة كلية الطب - جامعة عين شمس

الدكتور / إيمان محمد فوزى منتصر

مدرس طب المناطق الحارة كلية الطب - جامعة عين شمس

الدكتور/ محمد صبحى حسن

مدرس الاشعة التشخيصية كلية الطب - جامعة عين شمس

> كلية الطب جامعة عين شمس 2015

List Of Contents

List of Contents

| Title | Page No. |
|--|----------|
| List of Figures | II |
| List of Tables | IV |
| List of Abbreviations | IX |
| Introduction | 1 |
| Aim of the Work | 3 |
| Review of literature | |
| Chapter 1 Hepatocellular Carcinoma | 4 |
| Chapter 2 Trans arterial chemoembolization | 65 |
| Chapter 3 Porta vein thrombosis | 89 |
| Patients and Methods | 126 |
| Results | 139 |
| Discussion | 194 |
| Summary | 211 |
| Conclusion | 216 |
| Recommendations | 27 |
| References | 218 |
| Arabic Summary | |

List Of Figures

List of Figures

| | | _ |
|---------|-------|------|
| Fig. No | Title | Page |

Review

| _ | Barcelona Clinic Liver Cancer staging classification | |
|--------------|---|----|
| | and treatment Schedule4 | 13 |
| Figure (II) | : CUPI score | 4 |
| | : Recent modification in the proposed staging and treatment strategies for patients with HCC according to the BCLC | 19 |
| Figure (IV) | : Percutaneous ablation of HCC using RF5 | 55 |
| Figure (V) | : Key pathways in hepatocarcinogenesis 6 | 53 |
| Figure (VI) | : TACE of right lobe HCC6 | 57 |
| • | : HCC before and after TACE using Doxorubicin eluting beads | |
| Figure (VII) | I): Successful TACE of HCC7 | 19 |
| Figure (IX) | : Segmental anatomy of the liver9 | 0(|
| Figure (X) | : Portal, hepatic veins and IVC9 |)2 |
| Figure (XI) | : Diagram of portal circulation9 | 13 |
| _ | I): Criteria of HCC diagnosis were based on AASLD practice guidelines | 29 |
| | I): Recent modification in the proposed staging and treatment strategies for patients with HCC according to the BCLC | |

List Of Figures

Results

| Figure | (1): | Change in Child classification of patients before and after intervention | 18 |
|--------|-------------|---|----|
| Figure | | Relation between GH scale and response to intervention after three months |)1 |
| Figure | | Relation between functional scale and response to intervention after three months |)2 |
| Figure | ` ′ | Relation between symptoms scale and response to intervention after three months |)3 |

List of Tables

| Tab. No | Title F | Page |
|---------------------|---|------|
| | Review | |
| Table (I): | Groups for whom HCC surveillance recommended or in whom the risk of HCC increased. | |
| Table (II): | Sixth edition UICC TNM classification of HCC | 40 |
| Table (III): | Modified Sixth edition TNM classification of HCo is simplified into 4 stages to represent the optimus prognostic prediction | m |
| Table (IV): | OKUDA Staging System | 42 |
| Table (V): | Scoring for QLQ-C30 version 3 | 132 |
| Table(VI): | Evaluation of tumor response to ablation b imaging | - |
| | Results | |
| Table (1): | Demographic data and relevant medical history of the studied patients | |
| Table (2): | Clinical presentation at time of diagnosis in the studied patients | |
| Table (3): I | mportant laboratory result before intervention | 142 |
| Table (4): 1 | Pre-operative radiological details | 142 |
| Table (5): | : Total number of TACE after three months an decisions after one and three months | |
| Table (6): (| Comparison between the child classification before lafter one month and after three month of intervention | of |
| Table (7): | Patients' investigations, one month after intervention | |

List Of Tables

| Table(8): | Patients' investigations three months after intervention |
|--------------------|---|
| Table (9): | Relation between patients' response to treatment one Month after intervention and their personal data |
| Table (10): | Relation between patient's response to treatment one month after intervention and their investigations before intervention |
| Table (11): | Relation between patients' response to treatment three months after intervention and their personal data |
| Table (12): | Relation between patient's response to treatment three months after intervention and their investigations before intervention |
| Table (13): | Quality of life scores before, after 1 month and after three months of intervention |
| Table (14): | Relation between patients' Qol gilobal health scale before intervention and their personal data |
| Table (15): | Relation between patients' QOL functional scale before intervention and their personal data |
| Table (16): | Relation between patients' QOL symptoms scale before intervention and their personal data 157 |
| Table (17): | Relation between patients' QOL global health scale and their investigations before intervention . 159 |
| Table (18): | Relation between patients' QOL functional scale and their investigations before intervention 160 |
| Table (19): | Relation between patients' QOL symptoms scale and their investigations before intervention 161 |
| Table (20) | : Relation between patients' QOL Global health scale one month after intervention and their personal data |

List Of Tables

| Table(21): | Relation between patients' QOL functional scale one month after intervention and their personal data |
|--------------------|--|
| Table (22): | Relation between patients' QOL symptoms scale one month after intervention and their personal data |
| Table (23): | Relation between patients' QOL global health scale one month after intervention and their investigations before intervention |
| Table (24): | Relation between patients' QOL functional scale one month after intervention and their investigations before intervention |
| Table (25): | Relation between patients' QOL symptoms scale one month after intervention and their investigations before intervention |
| Table (26 | Relation between patients' QOL global health scale and their investigations one month after intervention |
| Table (27): | Relation between patients' QOL functional scale and their investigations one month after intervention |
| Table (28): | Relation between patients' QOL symptoms scale and their investigations one month after intervention |
| Table (29): | Relation between patients' QOL scores and their response to treatment one month after intervention 171 |
| Table (30): | Relation between patients' QOL global health scale three months after intervention and their personal data: |
| Table (31): | Relation between patients' QOL functional scale three months after intervention and their personal |

List Of Tables

| Table | (32): | Relation between patients' QOL symptoms scale three months after intervention and their personal data |
|---------|-------|---|
| Table | (33): | Relation between patients' QOL global health scale three months after intervention and their investigations before intervention |
| table (| (34): | Relation between patients' QOL functional scale three months after intervention and their investigations before intervention |
| Table | (35): | Relation between patients' QOL symptoms scale three months after intervention and their investigations before intervention |
| Table | (36): | Relation between patients' QOL global health scale and their investigations three months after intervention |
| Table | (37): | Relation between patients' QOL functional scale and their investigations three months after intervention |
| Table | (38): | Relation between patients' QOL symptoms scale and their investigations three months after intervention |
| Table | (39): | Relation between patients' QOL scores and their response to treatment three months after intervention |
| Table | (40): | Relation between QOL scores before and after intervention |
| Table | (41) | Relation between patients' QOL symptoms scale and their investigations three months after intervention |
| Table | (42): | Relation between patients' QOL scores and their response to treatment three months after intervention. |

| 🕮 List | Of | Tabl | es |
|--------|----|------|----|
|--------|----|------|----|

| Table | (43) | : | Relation | between | QOL | scores | before | and | after | |
|-------|-------------|----|------------|---------|-----|--------|--------|-----|-------|----|
| | | 11 | nterventio | n | | | | | 1 | 90 |

List of Abbreviations

| Abbrev. | Full term |
|--------------|--|
| 18F-FDG | Fluorine-18 fluorodeoxyglucose |
| 3 DCRT | Three dimension conformal radiation |
| | therapy |
| 90Y | Yatrium 90 |
| A1ATD | Alpha 1 antitrypsin deficiency |
| AASLD | American association for study of liver |
| | disease |
| AFB1 | Aflatoxin B 1 |
| AFP L 3 | Lens culinaris agglutinin-reactive alpha - |
| | fetoprotein |
| AFP | Alpha fetoprotein |
| AFT | Aflatoxin |
| AFU | Alpha L-Fucosidase |
| AJCC | American joint committee of cancer |
| APSVT | Acute porto splenic vein thrombosis |
| A-V | Arterio -venous |
| BCLC staging | Barcelona Clinic Liver Cancer staging |
| BCS | Budd charii syndrome |
| C- TACE | Conventional - Trans Arterial Chemo |
| | Embolization |
| CBD | Common bile duct |
| CD | Cluster of differentiation |
| CDUS | Colour Doppler ultrasound |
| CEUS | Contrast enhanced ultrasound |
| CHB | Chronic hepatitis B |
| CLD | Chronic liver Disease |
| CLIP staging | Cancer of liver Italian program staging |
| CLIP | Cancer liver Italian program |
| CR | Complete Response |
| CT | Computed Tomography |
| CUPI | The Chinese University Prognostic Index |
| CVs | Central Veins |
| DCP | Des-gama-carboxy prothrombin |
| | |

List Of Abbreviations

DEB Drug eluting beads

DEBDOX Doxorubicin drug eluting beads

DM Diabetes mellitus

DMSA Dimer capto succsinic acid DNA Deoxyribonucleic acid

DWMRI Diffussion-Weighted Magnetic Resonance

imaging

EASL European Association for study of the

Liver

EGF Epidermal growth factor

EGFR Epidermal growth factor recptor

ERCP Endoscopic Retrograde Cholangio-

Pancretography

ESLC Egyptian Society of Liver Cancer
EUS Endoscopic ultrasonography

FNA Fine Needle Aspiration FUO Fever of unknown origin . GGT Gama glutamyl transferase

GH Global health GPC3 Glypican-3

GRETCH Group d"Etude et Traintment du Carcinoma

Hepatocellulaire

HA Hepatic artery

HBPs Hepatobillary -pancreatic surgery

HBS Ag Hepatitis B surface antigen

HBV Hepatitis B virus

HBVxAg Hepatitis B virus x Antigen HCC Hepatocellular carcinoma

HCV Hepatitis C virus

HDGF Hepatoma derived growth factor

HDV Hepatitis D virus

HE Hepatic Encephalopathy

HFE Human haemochromatosis protein

HGF Hepatocyte growth Factor
HH Hereditary haemochromatosis

HIV Human Immuno -deficiency Virus

List Of Abbreviations

HR Hazard ratio

HSGGT Hepatoma Specific Gama glutamyl

transferase

HU h-7 Hepatoma cell line

IFN Interferon

IGF-2 Insulin growth factor 2
IGFs Insulin-like growth factors

IMRT Intensity modulated radiation therapy

IOUS Intra-operative ultrasonography

IVC Inferior vena cava

JIS Japan integrated staging score

LA Laser ablation

LCA Lens culinaris agglutinin

LCSGJ Liver Cancer Study Group of Japan LDLT Living donner liver transplantation

LITT Laser induced thermotherapy

LT Liver Transplantation

MA Metastatic adnocarcinoma

MC milan criteria
MDCT Multi-detector CT

MELD Model for end stage liver disease

MO Months

MPCT Multiphasic computrizied topography

MPD Myeloproliferative disorder

MRA Magnetic resonance angiography

MRCP Magnetic resonance cholangio-

pancreayography

MRI Magnetic resonance imaging

mRNA microrna

MRP Magnetic resonance portography

MSCT Multi-slice CT

MWA Microwave ablation

NAFLD Non alcoholic liver disease

NCCN National comprhensive cancer network
NICTH Non islet cell tumor hypoglycemia
OLT Orthotopic liver transplantation